Drugs / CTX0E03
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01151124 | Jun 2010 → Oct 2012 | ischemic stroke | ReNeuron Limited | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03629275 | Aug 2018 → Sep 2020 | hemiplegia, ischemic stroke | ReNeuron Limited | Terminated | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CTX0E03 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01151124 ↗ |
| Modality | Cell therapy | “CTX0E03 is an immortalised human neural stem-cell line from which a drug product (CTX-DP) was developed for allogeneic therapy.” PMID 27497862 ↗ Aug 2016 |
| Route | Other | “injected by stereotaxic procedures into the putamen region of the brain” NCT01151124 ↗ |